Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 304, Issue 4, 2013, Pages

  Sonne, David P ^a,c   Hare, Kristine J ^a   Martens, Pernille ^a   Rehfeld, Jens F ^b   Holst, Jens J ^c   Vilsbøll, Tina ^a,c   Knop, Filip K ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bile acids; Gallbladder; Incretins; TGR5

Indexed keywords

BILE ACID; C PEPTIDE; CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; BILE ACID BLOOD LEVEL; BODY MASS; CHOLECYSTECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; FAT INTAKE; FEMALE; GALLBLADDER EMPTYING; GASTRIN BLOOD LEVEL; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; INSULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; BILE ACIDS AND SALTS; BLOOD GLUCOSE; C-PEPTIDE; CHOLECYSTECTOMY; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 84874087110     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00435.2012     Document Type: Article

References (46)

1. Abramson DJ. Diabetes mellitus and cholecystectomy. Ann Surg 145: 371-378, 1957.
2. Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahrén B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 295: E779-E784, 2008.
3. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 25: 2020-2030, 2005.
4. Debas HT, Farooq O, Grossman MI. Inhibition of gastric emptying is a physiological action of cholecystokinin. Gastroenterology 68: 1211-1217, 1975.
5. De Santis A, Attili AF, Ginanni Corradini S, Scafato E, Cantagalli A, De Luca C, Pinto G, Lisi D, Capocaccia L. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology 25: 787-790, 1997.
6. Drucker DJ. Glucagon-like peptide 2. J Clin Endocrinol Metab 86: 1759-1764, 2001.
7. Dubé PE, Brubaker PL. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res 36: 755-760, 2004.
8. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138: 159-166, 1993.
9. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 30: 570-580, 2009.
10. Gomez G, Upp JR Jr, Lluis F, Alexander RW, Poston GJ, Greeley GH Jr, Thompson JC. Regulation of the release of cholecystokinin by bile salts in dogs and humans. Gastroenterology 94: 1036-1046, 1988.
11. Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H. Na-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion. Diabetes 61: 187-196, 2012.
12. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439, 2007.
13. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 36: 857-862, 1993.
14. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672, 1993.
15. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329: 386-390, 2005.
16. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M. A G protein-coupled receptor responsive to bile acids. J of Biol Chem 278: 9435-9440, 2003.
17. Kjems LL, Christiansen E, Vølund A, Bergman RN, Madsbad S. Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 49: 580-588, 2000.
18. Kjems LL, Vølund A, Madsbad S. Quantification of beta-cell function during IVGTT in Type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods. Diabetologia 44: 1339-1348, 2001.
19. Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab 299: E10-E13, 2010.
20. Koide M, Okabayashi Y, Otsuki M. Role of endogenous bile on basal and postprandial CCK release in humans. Dig Dis Sci 38: 1284-1290, 1993.
21. Koop I, Schindler M, Bosshammer A, Scheibner J, Stange E, Koop H. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids. Gut 39: 661-667, 1996.
22. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 9: 35-46, 1984.
23. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304, 1987.
24. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21: 2191-2192, 1998.
25. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298: 714-719, 2002.
26. Mashige F, Imai K, Osuga T. A simple and sensitive assay of total serum bile acids. Clin Chim Acta 70: 79-86, 1976.
27. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
28. McDonnell CO, Bailey I, Stumpf T, Walsh TN, Johnson CD. The effect of cholecystectomy on plasma cholecystokinin. Am J Gastroenterol 97: 2189-2192, 2002.
29. Medhus AW, Lofthus CM, Bredesen J, Husebye E. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterol Motil 13: 179-185, 2001.
30. Miceli JN, Aravind MK, Cohen SN, Done AK. Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography. Clin Chem 25: 1002-1004, 1979.
31. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
32. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87: 415-423, 1991.
33. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
34. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 17: 305-322, 2003.
35. Rabinowitch IM. The incidence of diabetes mellitus in diseases of the gall bladder and its passages (biometrical study). Can Med Assoc J 14: 296-297, 1924.
36. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem 44: 991-1001, 1998.
37. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 8: 532-539, 2008.
38. Stadil F, Rehfeld JF. Determination of gastrin in serum. An evaluation of the reliability of a radioimmunoassay. Scand J Gastroenterol 8: 101-112, 1973.
39. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10: 167-177, 2009.
40. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7: 678-693, 2008.
41. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86: 3853-3860, 2001.
42. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: 368-377, 1992.
43. Vignolo MC, Savassi-Rocha PR, Coelho LGV, Soares MP, Cardoso-Júnior A, Barbosa TFL, Ramos FV, Alves TR, Barbosa GM, Pinto DCG, Resende de C C, Boechat de C L, De Almeida AM. Gastric emptying before and after cholecystectomy in patients with cholecystolithiasis. Hepatogastroenterology 55: 850-854, 2008.
44. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 2706-2713, 2003.
45. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495, 2004.
46. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489, 2006.